John Arnold’s Post

Equity Research Analyst, Seth Basham, CFA®️ initiated coverage on Arhaus, Inc. (ARHS) at #NEUTRAL, setting a 12-month price target of $11.00. While the company has "strong premium furniture business and high growth potential," the team notes "macro and competition headwinds suggest limited room for upside in the near term." Read more about Seth's coverage universe here: https://wedbush.co/SBasham

Equity Research Analyst, Laura Chico, Ph.D., initiated coverage on Larimar Therapeutics, Inc. (LRMR) at #OUTPERFORM, setting a 12-month price target of $22.00. With LRMR’s lead program nomlabofusp (CTI-1601) advancement and recent nomination to FDA’s START pilot program, Laura and team think "this creates an attractive opportunity to launch coverage." Read more about Laura's coverage universe here: https://wedbush.co/LChico

Equity Research Analyst, David Nierengarten, Ph.D., initiates coverage on Perspective Therapeutics, Inc. (CATX) at #OUTPERFORM, setting a 12-month price target of $25.00. The Seattle, Washington-based radiopharmaceutical company's "targeted alpha therapy (TAT) programs are being developed to fight a variety of cancers." Read more about David's full coverage universe here: https://lnkd.in/grSnffWu

It’s back to school time around the country. For those of us who are trying to save for college and for their child’s education, it is a good time to review where we are at and if any adjustments are needed.

As we near the end of summer and move into September, much changes. Children are back in school. The focus for many sports fans shifts from baseball to football. We might see a heightened level of volatility between September and early to mid-November.

Our SVP, Equity Research, Matt Bryson, recently joined CNBC to break down semiconductor sentiment and analyze the evolving narrative around the sector.

Equity Research Analyst, David Nierengarten, Ph.D., initiated coverage on Oruka Therapeutics (ORKA), "a pre-clinical biopharmaceutical company developing biologics with optimized properties against validated targets in inflammatory skin conditions" and Spyre Therapeutics (SYRE), "a clinical-stage biopharmaceutical company developing biologics with optimized properties against validated targets in inflammatory bowel disease (IBD)," both at #OUTPERFORM. Stay tuned to see how these names perform, and read David's full coverage here: https://lnkd.in/grSnffWu

Equity Research Analyst, Laura Chico, Ph.D., initiated coverage on Alto Neuroscience (ANRO) at #OUTPERFORM, setting a 12-month price target of $29.00. This is "exactly what we've been looking for in CNS: precision-based strategies," notes Laura. "ANRO [...] fully embodies this strategy with biomarker-focused approaches to identify appropriate candidates across its development pipeline." Read more about Laura's coverage here: https://wedbush.co/3ALftPC

Equity Research Analyst, Jay McCanless, initiated coverage on Willdan Group ($WLDN) at #OUTPERFORM, setting a 12-month price target of $51.00. Because of the municipal, state and federal legislation dollars spent on energy efficiency, Jay sees Willdan as "positioned with a multi-decade runway of potential projects as cities and states revitalize older buildings via energy efficiency (EE) projects [...]." Read more about Jay's coverage here: https://wedbush.co/3yZZRqQ

With the 2024 presidential election just a few months away, it makes sense for investors to give some thought to the potential impact the results of the election might have on the economy, the financial markets and their portfolios.